A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC
NCT05879068 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99
Last updated 2024-12-18
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with paclitaxel as second line treatment for SCLC.
Conditions
Interventions
- DRUG
-
PM8002
IV infusion
- DRUG
-
IV infusion
Sponsors & Collaborators
-
Biotheus Inc.
lead INDUSTRY
Principal Investigators
-
Ying Cheng · Jilin Provincial Tumor Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-27
- Primary Completion
- 2025-04-30
- Completion
- 2026-04-30
Countries
- China
Study Locations
More Related Trials
-
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)
NCT05599789 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
NCT06028633 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Irinotecan Liposome(II) Combined With Ivonescimab as Second-line Treatment for Small Cell Lung Cancer : A Prospective, Single-arm, Multicenter Clinical Study
NCT06820762 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC
NCT04108013 ·Status: UNKNOWN ·Phase: PHASE2
-
A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
NCT05943795 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer
NCT03196986 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
NCT00866528 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC
NCT06769295 ·Status: RECRUITING ·Phase: PHASE2
-
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
NCT06929936 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
NCT07309276 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
NCT05543629 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.
NCT07009925 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
NCT00021060 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies
NCT04672928 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy
NCT04056949 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
NCT04023617 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
NCT02578680 ·Status: COMPLETED ·Phase: PHASE3
-
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
NCT05570825 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer
NCT02766140 ·Status: TERMINATED ·Phase: PHASE3
-
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer
NCT02016209 ·Status: UNKNOWN ·Phase: PHASE2
-
Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer
NCT04192682 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
NCT07082179 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05741021 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC
NCT05782426 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2